Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Department of Gastroenterology, Mayo Clinic, Rochester, MN, USA.
Clin Neurol Neurosurg. 2021 Aug;207:106774. doi: 10.1016/j.clineuro.2021.106774. Epub 2021 Jun 24.
Previous studies suggest deep brain stimulation of the subthalamic nucleus (STN-DBS) may improve olfaction and constipation in PD, using subjective measures.
To utilize objective measures to assess olfaction and constipation in PD following STN-DBS.
In this prospective pilot study, olfaction (University of Pennsylvania Smell Identification Test [UPSIT]), bowel symptoms (ROME III questionnaires, daily bowel diaries, 100 mm visual analog scales for satisfaction with treatment and bowel habits), and motor manifestations of PD were evaluated before and after STN-DBS. Levodopa equivalent daily dose (LEDD) was calculated.
Ten patients (8 men, mean age 67.4 ± 6.0 years) with mean PD duration of 7.5 ± 3.7 years underwent bilateral STN-DBS, with mean follow-up of 3 months for all measures, except 7 months follow-up for bowel diaries. There was improvement in the Unified Parkinson's Disease Rating Scale motor "off" scores (33.7 ± 6.7 before and 16.1 ± 10.8 after, P = 0.001). Mean UPSIT scores (20.0 ± 6.6 versus 17.5 ± 5.7, P = 0.03) worsened from severe to total hyposmia. Seven patients had baseline constipation and completed bowel diaries. There was improvement in number of complete spontaneous bowel motions (CBSM) per week (2.2 ± 1.9 before versus 4.7 ± 2.4 after, P = 0.04), satisfaction with treatment of constipation (44 ± 27 before versus 64 ± 25 after, P = 0.02), and with bowel motions (33 ± 22 before and 48 ± 20 after, P = 0.2). However, laxative use (P = 0.15) and LEDD (P = 0.15) were unchanged.
Olfaction worsened while symptoms of constipation improved but did not resolve after STN-DBS.
先前的研究表明,通过刺激丘脑底核(STN)可以改善帕金森病(PD)患者的嗅觉和便秘,这是通过主观指标来衡量的。
利用客观指标来评估 STN-DBS 对 PD 患者的嗅觉和便秘的影响。
在这项前瞻性的初步研究中,使用宾夕法尼亚大学嗅觉识别测试(UPSIT)评估嗅觉,使用罗马 III 问卷(ROME III questionnaires)、日常排便日记、100 毫米视觉模拟量表(用于评估治疗满意度和排便习惯)评估排便症状,并在 STN-DBS 前后评估 PD 的运动表现。计算左旋多巴等效日剂量(LEDD)。
10 名患者(8 名男性,平均年龄 67.4 ± 6.0 岁)接受了双侧 STN-DBS,所有指标的平均随访时间为 3 个月,除了排便日记的随访时间为 7 个月。统一帕金森病评定量表运动“关”期评分从 33.7 ± 6.7 降低至 16.1 ± 10.8(P = 0.001)。UPSIT 评分均值从 20.0 ± 6.6 降低至 17.5 ± 5.7(P = 0.03),从严重嗅觉减退变为完全嗅觉减退。7 名基线时存在便秘的患者完成了排便日记。每周完全自发排便次数(CBSM)从 2.2 ± 1.9 增加至 4.7 ± 2.4(P = 0.04),对便秘治疗的满意度从 44 ± 27 提高至 64 ± 25(P = 0.02),对排便的满意度从 33 ± 22 提高至 48 ± 20(P = 0.2)。然而,通便药物的使用(P = 0.15)和 LEDD(P = 0.15)没有变化。
STN-DBS 后,嗅觉恶化,便秘症状改善但未得到解决。